Harnessing Continuous Glucose Monitors for Type 1 Diabetes Management + Closing Words

Robert Gabbay, MD, PhD, gives closing thoughts and advocates that continuous glucose monitors should be supplied for all insulin-dependent diabetes patients, including at initial diagnosis, to facilitate self-management and tighter control of this disease.

EP: 1.Unraveling Type 1 Diabetes: Differences Between Type 1 and Type 2

EP: 2.Early-stage Type 1 Diabetes and The Psychological Impact of Progressing to Stage 3

EP: 3.Identifying Risk to Enable Early Detection of Type 1 Diabetes

EP: 4.Challenges in Autoantibody Screening for Type 1 Diabetes

EP: 5.Strategies for Preventing Progression of Early-Stage Type 1 Diabetes

EP: 6.Optimal Approaches to Diagnostic Testing for Type 1 Diabetes Mellitus

Now Viewing

EP: 7.Harnessing Continuous Glucose Monitors for Type 1 Diabetes Management + Closing Words

Related Videos

Related Content

Advertisement

June 18th 2025

Twice-Yearly Lenacapavir Approval Marks Major Milestone in Prevention of HIV

Julia Bonavitacola

The FDA approval marks the first approval of a type of pre-exposure prophylaxis that would only require 2 treatments per year.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

June 16th 2025

Methotrexate Adds No Benefit to Adalimumab in Psoriasis Treatment, Study Suggests

Pearl Steinzor

Target trial emulation study finds no added effectiveness or persistence with combination therapy for plaque psoriasis.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

June 14th 2025

A Look at Those With Durable Responses to Epcoritamab in LBCL

Mary Caffrey

A post-hoc analysis of EPCORE-NHL-1 was presented at ASCO.

June 14th 2025

EHA Plenary Abstracts Zoom in From Investigational Drugs to Molecular Signatures

Christina Mattina

Abstracts presented during the plenary session of the 2025 European Hematology Association (EHA) Congress spanned from novel drug regimens for myeloma and lymphoma to investigation of leukemias on the molecular and genetic levels.

Related Content

Advertisement

June 18th 2025

Twice-Yearly Lenacapavir Approval Marks Major Milestone in Prevention of HIV

Julia Bonavitacola

The FDA approval marks the first approval of a type of pre-exposure prophylaxis that would only require 2 treatments per year.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

June 16th 2025

Methotrexate Adds No Benefit to Adalimumab in Psoriasis Treatment, Study Suggests

Pearl Steinzor

Target trial emulation study finds no added effectiveness or persistence with combination therapy for plaque psoriasis.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

June 14th 2025

A Look at Those With Durable Responses to Epcoritamab in LBCL

Mary Caffrey

A post-hoc analysis of EPCORE-NHL-1 was presented at ASCO.

June 14th 2025

EHA Plenary Abstracts Zoom in From Investigational Drugs to Molecular Signatures

Christina Mattina

Abstracts presented during the plenary session of the 2025 European Hematology Association (EHA) Congress spanned from novel drug regimens for myeloma and lymphoma to investigation of leukemias on the molecular and genetic levels.